Literature DB >> 22064716

Repeated exposure to Aspergillus fumigatus conidia results in CD4+ T cell-dependent and -independent pulmonary arterial remodeling in a mixed Th1/Th2/Th17 microenvironment that requires interleukin-4 (IL-4) and IL-10.

Andrew B Shreiner1, Benjamin J Murdock, Amir A Sadighi Akha, Nicole R Falkowski, Paul J Christensen, Eric S White, Cory M Hogaboam, Gary B Huffnagle.   

Abstract

Pulmonary arterial remodeling is a pathological process seen in a number of clinical disease states, driven by inflammatory cells and mediators in the remodeled artery microenvironment. In murine models, Th2 cell-mediated immune responses to inhaled antigens, such as purified Aspergillus allergen, have been reported to induce remodeling of pulmonary arteries. We have previously shown that repeated intranasal exposure of healthy C57BL/6 mice to viable, resting Aspergillus fumigatus conidia leads to the development of chronic pulmonary inflammation and the coevolution of Th1, Th2, and Th17 responses in the lungs. Our objective was to determine whether repeated intranasal exposure to Aspergillus conidia would induce pulmonary arterial remodeling in this mixed Th inflammatory microenvironment. Using weekly intranasal conidial challenges, mice developed robust pulmonary arterial remodeling after eight exposures (but not after two or four). The process was partially mediated by CD4+ T cells and by interleukin-4 (IL-4) production, did not require eosinophils, and was independent of gamma interferon (IFN-γ) and IL-17. Furthermore, remodeling could occur even in the presence of strong Th1 and Th17 responses. Rather than serving an anti-inflammatory function, IL-10 was required for the development of the Th2 response to A. fumigatus conidia. However, in contrast to previous studies of pulmonary arterial remodeling driven by the A. fumigatus allergen, viable conidia also stimulated pulmonary arterial remodeling in the absence of CD4+ T cells. Remodeling was completely abrogated in IL-10-/- mice, suggesting that a second, CD4+ T cell-independent, IL-10-dependent pathway was also driving pulmonary arterial remodeling in response to repeated conidial exposure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22064716      PMCID: PMC3255686          DOI: 10.1128/IAI.05530-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

1.  Role of IL-10 in invasive aspergillosis: increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosis.

Authors:  K V Clemons; G Grunig; R A Sobel; L F Mirels; D M Rennick; D A Stevens
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus.

Authors:  Silvia Bozza; Roberta Gaziano; Antonio Spreca; Angela Bacci; Claudia Montagnoli; Paolo di Francesco; Luigina Romani
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

3.  Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling.

Authors:  Zorina S Galis; Chad Johnson; Denis Godin; Richard Magid; J Michael Shipley; Robert M Senior; Eugen Ivan
Journal:  Circ Res       Date:  2002-11-01       Impact factor: 17.367

Review 4.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  Interleukin-10 gene transfer to the airway regulates allergic mucosal sensitization in mice.

Authors:  M R Stämpfli; M Cwiartka; B U Gajewska; D Alvarez; S A Ritz; M D Inman; Z Xing; M Jordana
Journal:  Am J Respir Cell Mol Biol       Date:  1999-11       Impact factor: 6.914

6.  IL-10 deficiency prevents IL-5 overproduction and eosinophilic inflammation in a murine model of asthma-like reaction.

Authors:  X Yang; S Wang; Y Fan; X Han
Journal:  Eur J Immunol       Date:  2000-02       Impact factor: 5.532

Review 7.  Respiratory fungal allergy.

Authors:  V P Kurup; H D Shen; B Banerjee
Journal:  Microbes Infect       Date:  2000-07       Impact factor: 2.700

8.  Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus.

Authors:  J K Brieland; C Jackson; F Menzel; D Loebenberg; A Cacciapuoti; J Halpern; S Hurst; T Muchamuel; R Debets; R Kastelein; T Churakova; J Abrams; R Hare; A O'Garra
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

9.  Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model.

Authors:  Susan M Lessner; Heather L Prado; Edmund K Waller; Zorina S Galis
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

10.  Remodeling of extra-bronchial lung vasculature following allergic airway inflammation.

Authors:  Kristina Rydell-Törmänen; Lena Uller; Jonas S Erjefält
Journal:  Respir Res       Date:  2008-02-08
View more
  23 in total

1.  IL-1RA regulates immunopathogenesis during fungal-associated allergic airway inflammation.

Authors:  Matthew S Godwin; Kristen M Reeder; Jaleesa M Garth; Jonathan P Blackburn; MaryJane Jones; Zhihong Yu; Sadis Matalon; Annette T Hastie; Deborah A Meyers; Chad Steele
Journal:  JCI Insight       Date:  2019-11-01

2.  Eosinophils are recruited in response to chitin exposure and enhance Th2-mediated immune pathology in Aspergillus fumigatus infection.

Authors:  Evan M O'Dea; Nansalmaa Amarsaikhan; Hongtao Li; Joshua Downey; Emery Steele; Steven J Van Dyken; Richard M Locksley; Steven P Templeton
Journal:  Infect Immun       Date:  2014-05-19       Impact factor: 3.441

Review 3.  Hyaluronan fragments as mediators of inflammation in allergic pulmonary disease.

Authors:  Sumit Ghosh; Scott A Hoselton; Glenn P Dorsam; Jane M Schuh
Journal:  Immunobiology       Date:  2014-12-31       Impact factor: 3.144

4.  Evolution of the Immune Response to Chronic Airway Colonization with Aspergillus fumigatus Hyphae.

Authors:  Mirjam Urb; Brendan D Snarr; Gabriella Wojewodka; Mélanie Lehoux; Mark J Lee; Benjamin Ralph; Maziar Divangahi; Irah L King; Toby K McGovern; James G Martin; Richard Fraser; Danuta Radzioch; Donald C Sheppard
Journal:  Infect Immun       Date:  2015-06-29       Impact factor: 3.441

5.  Hyaluronan stimulates ex vivo B lymphocyte chemotaxis and cytokine production in a murine model of fungal allergic asthma.

Authors:  Sumit Ghosh; Scott A Hoselton; Steve B Wanjara; Jennifer Carlson; James B McCarthy; Glenn P Dorsam; Jane M Schuh
Journal:  Immunobiology       Date:  2015-02-07       Impact factor: 3.144

6.  Interleukin-17 drives pulmonary eosinophilia following repeated exposure to Aspergillus fumigatus conidia.

Authors:  Benjamin J Murdock; Nicole R Falkowski; Andrew B Shreiner; Amir A Sadighi Akha; Roderick A McDonald; Eric S White; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2012-01-17       Impact factor: 3.441

7.  Interleukin-17A enhances host defense against cryptococcal lung infection through effects mediated by leukocyte recruitment, activation, and gamma interferon production.

Authors:  Benjamin J Murdock; Gary B Huffnagle; Michal A Olszewski; John J Osterholzer
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

Review 8.  Allergic Inflammation in Aspergillus fumigatus-Induced Fungal Asthma.

Authors:  Sumit Ghosh; Scott A Hoselton; Jane M Schuh
Journal:  Curr Allergy Asthma Rep       Date:  2015-10       Impact factor: 4.806

9.  Lung Epithelial Cell-Derived Microvesicles Regulate Macrophage Migration via MicroRNA-17/221-Induced Integrin β1 Recycling.

Authors:  Heedoo Lee; Duo Zhang; Jingxuan Wu; Leo E Otterbein; Yang Jin
Journal:  J Immunol       Date:  2017-07-03       Impact factor: 5.422

10.  Eosinophil deficiency compromises lung defense against Aspergillus fumigatus.

Authors:  Lauren M Lilly; Michaella Scopel; Michael P Nelson; Ashley R Burg; Chad W Dunaway; Chad Steele
Journal:  Infect Immun       Date:  2013-12-30       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.